CoChat
Sign Up
Cited by 33Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesMental Health Treatment and Access

Desvenlafaxine for the Prevention of Relapse in Major Depressive Disorder: Results of a Randomized Trial

Rickels, Karl, Montgomery, Stuart A., Tourian, Karen A., Guelfi, Julien D., Pitrosky, Bruno, Padmanabhan, Sudharshan Krishna, Germain, Jean-Michael, Leurent, Claire +1 more·2010·Journal of Clinical Psychopharmacology
DOI 10.1097/jcp.0b013e3181c94c4d
Open this paper in CoChat — free account

Abstract

OBJECTIVES: To compare the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) with placebo in reducing relapse rate in patients with major depressive disorder (MDD). METHODS: This phase 3, multicenter, randomized trial included a 12-week, open-label (OL) treatment phase (intent-to-treat population, n = 575) followed by a 6-month, double-blind (DB) relapse prevention phase. Patients who responded to the OL treatment (17-item Hamilton Rating Scale for Depression total score or= 16 at any visit, Clinical Global Impression-Improvement score >or= 6 at any visit, or discontinuation due to unsatisfactory response). RESULTS: Patients receiving desvenlafaxine (n = 189) experienced significantly longer times to relapse of MDD versus patients receiving placebo (n = 185) during the DB period (log-rank test, P < 0.0001). The percentages of patients relapsing were 42% (78/185) and 24% (45/189) for placebo and desvenlafaxine, respectively (P < 0.001). The most common primary reason cited for discontinuation in the OL period was adverse events (19%), which consisted of nausea, dizziness, and insomnia. A total of 159 patients (42%) discontinued treatment during the DB period, including 101 placebo- (55%) and 58 desvenlafaxine-treated patients (31%). The most frequent adverse event reported as reason for treatment discontinuation in the DB period was depression, reported by 14 placebo- (8%) and 7 desvenlafaxine-treated patients (4%). CONCLUSIONS: Desvenlafaxine effectively prevented relapse of MDD during 6 months of DB treatment in patients who had responded to 12 weeks of OL desvenlafaxine therapy.

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e3181c94c4d

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The results of the first levomilnacipran ER relapse-prevention study are inconsistent with relapse-prevention outcomes reported in the literature for trials of other SNRIs versus placebo (e.g., venlafaxine, 28% vs. 52%; desvenlafaxine, 24% vs. 42%; duloxetine, 21.9% vs. 43.1%).

    “the results of the first levomilnacipran ER relapse‐prevention study are inconsistent with relapse‐prevention outcomes reported in the literature for trials of other SNRIs versus placebo (e.g., venlafaxine, 28% vs. 52%; desvenlafaxine, 24% vs. 42%; duloxetine, 21.9% vs. 43.1%; Perahia et al., 2006; Rickels et al., 2010; Simon, Aguiar, Kunz, & Lei, 2004).”

    From Relapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study (2019) · cites this paper as Rickels et al., 2010

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Rickels, K., Montgomery, S. A., Tourian, K. A., Guelfi, J. D., Pitrosky, B., Padmanabhan, S. K., Germain, J.-M., Leurent, C., & Brisard, C.
Affiliations
  • University of Pennsylvania (US)
  • Imperial College London (GB)
  • Wyeth (US)
  • Centre Hospitalier Sainte-Anne (FR)
  • Pfizer (France) (FR)
Corresponding author
Rickels, Karl
ORCID
Montgomery, Stuart A.
Venue
Journal of Clinical Psychopharmacology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2010-02
Volume
30
Issue
1
Pages
18-24
ISSN
0271-0749 (ISSN-L)
DOI
10.1097/jcp.0b013e3181c94c4d
OpenAlex
W2011850312
Cited by
33
References
23
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 4 · 2014: 1 · 2013: 5
FWCI
2.35
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
Keywords
desvenlafaxine, major depressive disorder, relapse prevention, antidepressant efficacy, adverse events, treatment discontinuation, serotonin-norepinephrine reuptake inhibitors
MeSH terms
Desvenlafaxine Succinate, Adult, Antidepressive Agents, Cyclohexanols, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Psychiatric Status Rating Scales, Treatment Outcome, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review